Literature DB >> 9171363

Developmentally regulated initiation of DNA synthesis by telomerase: evidence for factor-assisted de novo telomere formation.

J Bednenko1, M Melek, E C Greene, D E Shippen.   

Abstract

Telomerase serves a dual role at telomeres, maintaining tracts of telomere repeats and forming telomeres de novo on broken chromosomes in a process called chromosome healing. In ciliates, both mechanisms are readily observed. Vegetatively growing cells maintain pre-existing telomeres, while cells undergoing macronuclear development fragment their chromosomes and form telomeres de novo. Here we provide the first evidence for developmentally regulated initiation of DNA synthesis by telomerase. In vitro assays were conducted with telomerase from vegetative and developing Euplotes macronuclei using chimeric primers that contained non-telomeric 3' ends and an upstream stretch of telomeric DNA. In developing macronuclei, chimeric primers had two fates: nucleotides were either polymerized directly onto the 3' terminus or residues were removed from the 3' end by endonucleolytic cleavage before polymerization began. In contrast, telomerase from vegetative macronuclei used only the cleavage pathway. Telomere repeat addition onto non-telomeric 3' ends was lost when developing macronuclei were lysed and the contents purified on glycerol gradients. However, when fractions from the glycerol gradient were added back to partially purified telomerase, telomere synthesis was restored. The data indicate that a dissociable chromosome healing factor (CHF) collaborates with telomerase to initiate developmentally programmed de novo telomere formation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9171363      PMCID: PMC1169850          DOI: 10.1093/emboj/16.9.2507

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  51 in total

1.  The Stability of Broken Ends of Chromosomes in Zea Mays.

Authors:  B McClintock
Journal:  Genetics       Date:  1941-03       Impact factor: 4.562

2.  Recognition of a chromosome truncation site associated with alpha-thalassaemia by human telomerase.

Authors:  G B Morin
Journal:  Nature       Date:  1991-10-03       Impact factor: 49.962

3.  Origin of concatemeric T7 DNA.

Authors:  J D Watson
Journal:  Nat New Biol       Date:  1972-10-18

4.  The controlling sequence for site-specific chromosome breakage in Tetrahymena.

Authors:  M C Yao; C H Yao; B Monks
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

5.  Boundary elements of the Tetrahymena telomerase RNA template and alignment domains.

Authors:  C Autexier; C W Greider
Journal:  Genes Dev       Date:  1995-09-15       Impact factor: 11.361

Review 6.  General initiation factors for RNA polymerase II.

Authors:  R C Conaway; J W Conaway
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

7.  Tetrahymena telomerase catalyzes nucleolytic cleavage and nonprocessive elongation.

Authors:  K Collins; C W Greider
Journal:  Genes Dev       Date:  1993-07       Impact factor: 11.361

8.  Telomere terminal transferase activity from Euplotes crassus adds large numbers of TTTTGGGG repeats onto telomeric primers.

Authors:  D Shippen-Lentz; E H Blackburn
Journal:  Mol Cell Biol       Date:  1989-06       Impact factor: 4.272

9.  Oligonucleotides complementary to the Oxytricha nova telomerase RNA delineate the template domain and uncover a novel mode of primer utilization.

Authors:  M Melek; B T Davis; D E Shippen
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

10.  Characterization of chromosome fragmentation in two protozoans and identification of a candidate fragmentation sequence in Euplotes crassus.

Authors:  S E Baird; L A Klobutcher
Journal:  Genes Dev       Date:  1989-05       Impact factor: 11.361

View more
  27 in total

1.  Interference footprinting analysis of telomerase elongation complexes.

Authors:  S Benjamin; N Baran; H Manor
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

2.  De novo telomere addition to spacer sequences prior to their developmental degradation in Euplotes crassus.

Authors:  Matthias Möllenbeck; Lawrence A Klobutcher
Journal:  Nucleic Acids Res       Date:  2002-01-15       Impact factor: 16.971

3.  Rapid upregulation of telomerase activity in human leukemia HL-60 cells treated with clinical doses of the DNA-damaging drug etoposide.

Authors:  T J Moriarty; S Dupuis; C Autexier
Journal:  Leukemia       Date:  2002-06       Impact factor: 11.528

Review 4.  Pharmacological approaches to defining the role of chaperones in aging and prostate cancer progression.

Authors:  Sarah A Harvey; Keith O Jensen; Lynne W Elmore; Shawn E Holt
Journal:  Cell Stress Chaperones       Date:  2002-04       Impact factor: 3.667

5.  dGTP-dependent processivity and possible template switching of euplotes telomerase.

Authors:  P W Hammond; T R Cech
Journal:  Nucleic Acids Res       Date:  1997-09-15       Impact factor: 16.971

6.  A human telomerase-associated nuclease.

Authors:  Rena Oulton; Lea Harrington
Journal:  Mol Biol Cell       Date:  2004-04-30       Impact factor: 4.138

7.  The Euplotes telomerase subunit p43 stimulates enzymatic activity and processivity in vitro.

Authors:  Stefan Aigner; Thomas R Cech
Journal:  RNA       Date:  2004-07       Impact factor: 4.942

8.  A conserved telomerase motif within the catalytic domain of telomerase reverse transcriptase is specifically required for repeat addition processivity.

Authors:  Neal F Lue; You-Chin Lin; I Saira Mian
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

9.  RNA-template dependent de novo telomere addition.

Authors:  Gloria Fuhrmann; Franziska Jönsson; Patrick Philipp Weil; Jan Postberg; Hans J Lipps
Journal:  RNA Biol       Date:  2016-01-19       Impact factor: 4.652

10.  Oligomerization of the telomerase reverse transcriptase from Euplotes crassus.

Authors:  Libin Wang; Sierra R Dean; Dorothy E Shippen
Journal:  Nucleic Acids Res       Date:  2002-09-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.